Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 08/07/25
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025GlobeNewsWire • 07/31/25
Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/12/25
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 05/12/25
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025GlobeNewsWire • 04/28/25
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® FranchiseGlobeNewsWire • 04/14/25
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 03/25/25
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 03/10/25
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025GlobeNewsWire • 03/03/25
Coherus Management to Participate at the 45th Annual TD Cowen Health Care ConferenceGlobeNewsWire • 02/24/25
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025GlobeNewsWire • 12/18/24
Coherus Management to Participate in the 2024 Citi Global Healthcare ConferenceGlobeNewsWire • 11/27/24
Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/06/24